ClinicalTrials.gg
CompletedNCT00643201Updated Apr 21, 2014Results posted

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

A Phase 3 interventional study of Enoxaparin and warfarin in Venous Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 382 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,614
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.

Enrollment
2nd of 26
5,614 · median 445
Started
2008
with 1 other
Phase 3
10 of 26
1 open now
Registered
6th of 26
by date
Lead sponsor
6 of 26
Bristol-Myers Squibb

Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 6th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing apixaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)

03

Conditions studied

  • Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • Clinical diagnosis of DVT or PE

Exclusion criteria

Exclusion Criteria:

  • for enoxaparin or warfarin
  • Active bleeding or high risk for serious bleeding
  • Short
  • Uncontrolled high blood pressure
  • Significantly impaired kidney or liver function
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5,614 participants (actual)

Study arms

  • Active comparator
    Apixaban

    apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.

    Drug: Enoxaparin · Drug: warfarin · Drug: Placebo for apixaban

  • Experimental
    Enoxaparin + Warfarin

    Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.

    Drug: Placebo for enoxaparin · Drug: Placebo for warfarin · Drug: apixaban

Interventions

  • solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.

  • tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months

    Also known as: Coumadin, BMS-565793

  • DrugPlacebo for apixaban

    tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

  • DrugPlacebo for enoxaparin

    solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.

  • DrugPlacebo for warfarin

    tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

  • tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months

    Also known as: BMS-562247

06

What researchers measure

Primary outcomes

  1. Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment

    VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).

    Time frame: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)

Secondary outcomes

  1. Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death

    VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.

    Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

  2. Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death

    VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.

    Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

  3. Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding

    VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle

    Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

  4. Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding

    VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).

    Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

  5. Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period

    DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).

    Time frame: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

  6. Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period

    PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).

    Time frame: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)

  7. Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period

    VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  8. Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period

    VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  9. Incidence of All-Cause Death During the Intended Treatment Period

    Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  10. Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants

    All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  11. Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants

    Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  12. Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants

    Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  13. Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants

    Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  14. Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants

    Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  15. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants

    Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued

  16. Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests

    Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: \< 0.75\*LLN, \> 1.25\*ULN; Hemoglobin: \<= 11.5 g/dL (males), \<= 9.5 g/dL (females); Hematocrit: \<= 37% (males), \<= 32% (females); Erythrocytes: \<0.75\*10\^6 c/µL\*PreRx; Platelet count: \< 75\*10\^9 c/L, \> 700\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.750\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes\> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL, \> 7.5\*10\^3 c/ µL.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  17. Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests

    Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if pre-dose \< LLN then use \< 0.95\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.05\*pre-dose or \< LLN.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  18. Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests

    Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  19. Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests

    Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use 0.9\* pre-dose or \> ULN if pre-dose \> ULN then use 1.1 \*pre-dose or \<LLN; Uric acid High: \> 1.5\* ULN, or if pre-dose \> ULN then use \> 2 \*pre-dose.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

  20. Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests

    All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.

    Time frame: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

07

Results

Posted Apr 10, 2014

Participant flow

First participant, first visit: 27 August 2008; Last participant, last visit: 12 March 2013.

Randomized, Completed 6 Months of Study
Participant flow — Randomized, Completed 6 Months of Study
MilestoneApixabanEnoxaparin + Warfarin
Started26912704
Completed23142291
Not completed377413
Withdrew: Death2026
Withdrew: Adverse event150182
Withdrew: Withdrawal by subject4949
Withdrew: Lost to follow-up1414
Withdrew: Poor or non-compliance2023
Withdrew: Pregnancy32
Withdrew: Fails to meet inclusion/exclusion139
Withdrew: Administrative reason11
Withdrew: Other107107
Completed Study Follow Up
Participant flow — Completed Study Follow Up
MilestoneApixabanEnoxaparin + Warfarin
Started26172639
Completed25472560
Not completed7079
Withdrew: Death2834
Withdrew: Withdrawal by subject2329
Withdrew: Lost to follow-up1816
Withdrew: Non-specified10

Outcome measures

PrimaryIncidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment

VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).

Time frame:
Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment0.0226 (0.0169 to 0.0283)0.0269 (0.0208 to 0.0331)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Yanagawa-Tango-Hiejima · p = <0.0001 (This is the first test in a sequential testing sequence. p-value calculated based on the Yanagawa-Tango-Hiejima test stratified by index event strata for non-inferiority. Tested at 1-sided α=0.025) · Risk ratio (rr): 0.8390 · 95% CI 0.5965 to 1.1802For a successful trial; rejection of the null hypotheses for both RR and RD was required.
  • Apixaban vs Enoxaparin + Warfarin · Yanagawa-Tango-Hiejima · p = <0.0001 (Yanagawa-Tango-Hiejima test statistic for risk difference (RD).) · Risk difference (rd): -0.0044 · 95% CI -0.0128 to 0.0040
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = 0.3128 (Tested at 2-sided α=0.05 significance. Further inferential statistical testing halted due to failure to reject the null hypothesis of equivalence for VTE/VTE-related death.) · Risk ratio (rr): 0.8390 · 95% CI 0.5965 to 1.1802Relative risk, CI, and p-value were calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.

Time frame:
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death0.0322 (0.0254 to 0.0390)0.0395 (0.0320 to 0.0469)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = 0.1554 (The test was stratified by index event strata using alpha=0.05 level of significance. Analysis was performed on the secondary efficacy dataset; there was no imputation of missing data.) · Risk ratio (rr): 0.8151 · 95% CI 0.6146 to 1.0812Nominal p-value is reported.
SecondaryIncidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.

Time frame:
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death0.0234 (0.0176 to 0.0292)0.0292 (0.0228 to 0.0357)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = 0.1848 (The test was stratified by index event strata using alpha=0.05 level of significance. . Nominal p-value is reported.) · Risk ratio (rr): 0.7994 · 95% CI 0.5737 to 1.1137Analysis was performed on the secondary efficacy dataset; there was no imputation of missing data.
SecondaryIncidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle

Time frame:
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding0.0280 (0.0216 to 0.0343)0.0448 (0.0369 to 0.0527)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = 0.0011 (The test was stratified by index event strata using alpha=0.05 level of significance. Nominal p-value is reported.) · Risk ratio (rr): 0.6236 · 95% CI 0.4682 to 0.8306
SecondaryIncidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding

VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).

Time frame:
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding0.0699 (0.0602 to 0.0797)0.1261 (0.1134 to 0.1387)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = <0.0001 (The test was stratified by index event strata using alpha=0.05 level of significance. Nominal p-value is reported.) · Risk ratio (rr): 0.5532 · 95% CI 0.4658 to 0.6569
SecondaryIncidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period

DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).

Time frame:
Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period0.0084 (0.0049 to 0.0119)0.0133 (0.0089 to 0.0177)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.6347 · 95% CI 0.3735 to 1.0787Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period

PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).

Time frame:
Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period0.0104 (0.0065 to 0.0142)0.0095 (0.0058 to 0.0132)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · Risk ratio (rr): 1.0935 · 95% CI 0.6363 to 1.8793Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period

VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period0.0046 (0.0020 to 0.0072)0.0061 (0.0031 to 0.0091)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.7521 · 95% CI 0.3560 to 1.5889Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period

VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period0.0058 (0.0028 to 0.0087)0.0087 (0.0052 to 0.0123)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.6539 · 95% CI 0.3419 to 1.2508Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of All-Cause Death During the Intended Treatment Period

Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of All-Cause Death During the Intended Treatment Period
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of All-Cause Death During the Intended Treatment Period0.0157 (0.0109 to 0.0205)0.0198 (0.0145 to 0.0251)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · Risk ratio (rr): 0.7934 · 95% CI 0.5287 to 1.1906Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants

All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants0.0056 (0.0028 to 0.0084)0.0182 (0.0132 to 0.0233)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = <0.0001 (p-value calculated on the CMH test stratified by index event strata.) · Risk ratio (rr): 0.3070 · 95% CI 0.1728 to 0.5452Relative risk and CI were calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants

Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants0.0430 (0.0353 to 0.0507)0.0971 (0.0859 to 0.1083)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = <0.0001 (Tested at 2-sided alpha=0.05 significance.) · Risk ratio (rr): 0.4410 · 95% CI 0.3566 to 0.5453Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants0.0385 (0.0312 to 0.0458)0.0800 (0.0697 to 0.0902)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = <0.0001 (Tested at 2-sided alpha=0.05 significance.) · Risk ratio (rr): 0.4793 · 95% CI 0.3815 to 0.6022Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants0.1170 (0.1048 to 0.1291)0.1878 (0.1730 to 0.2026)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = <0.0001 (Tested at 2-sided alpha=0.05 significance.) · Risk ratio (rr): 0.6182 · 95% CI 0.5432 to 0.7034Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryIncidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · proportion of participants
Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants
proportion of participantsApixabanEnoxaparin + Warfarin
Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants0.1502 (0.1367 to 0.1638)0.2514 (0.2350 to 0.2678)
Statistical analysis
  • Apixaban vs Enoxaparin + Warfarin · Cochran-Mantel-Haenszel · p = <0.0001 (Tested at 2-sided alpha=0.05 significance.) · Risk ratio (rr): 0.5937 · 95% CI 0.5318 to 0.6629Relative Risk and CI was calculated based on CMH test stratified by index event strata.
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants

Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants
participantsApixabanEnoxaparin + Warfarin
AE17951923
SAE417410
Bleeding AE or SAE415695
Discontinued Due to AE or SAE162199
Death3744
SecondaryNumber of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests

Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: \< 0.75\*LLN, \> 1.25\*ULN; Hemoglobin: \<= 11.5 g/dL (males), \<= 9.5 g/dL (females); Hematocrit: \<= 37% (males), \<= 32% (females); Erythrocytes: \<0.75\*10\^6 c/µL\*PreRx; Platelet count: \< 75\*10\^9 c/L, \> 700\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.750\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes\> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL, \> 7.5\*10\^3 c/ µL.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · participants
Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests
participantsApixabanEnoxaparin + Warfarin
Erthrocytes Low (N=2599, 2593)2317
Hematocrit Low (N=2588, 2587)2620
Hemoglobin Low (N=2599, 2593)96101
Platelet Count Low (N=2594, 2589)2313
Leukocytes Low (N=2528, 2519)4141
Leukocytes High (N=2528, 2519)2615
Absolute Basophils High (N=2594,2589)12
Absolute Eosinophils High (N=2594,2589)8479
Absolute Lyphocytes Low (N=2594,2589)9476
Absolute Lyphocytes High (N=2594,2589)43
Absolute Monocytes High (N=2594,2589)12
Absolute Neutrophils Low (N=2594,2589)920
SecondaryNumber of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests

Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if pre-dose \< LLN then use \< 0.95\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.05\*pre-dose or \< LLN.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · participants
Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests
participantsApixabanEnoxaparin + Warfarin
Bicarbonate Low (N=2600,2593)4431
Bicarbonate High (N=2600,2593)1711
Total Calcium Low (N=2601,2596)310
Total Calcium High (N=2601,2596)1211
Chloride Low Total Calcium Low (N=2601,2596)53
Chloride Low Total Calcium High (N=2601,2596)01
Potassium Low (N=2601,2596)2622
Potassium High (N=2601,2596)1922
Sodium Low (N=2601,2596)106
Sodium Low (N=2601,2596)44
SecondaryNumber of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests

Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · participants
Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests
participantsApixabanEnoxaparin + Warfarin
BUN High (N=517, 523)27
Creatinine High (N=2601, 2596)4737
ALT High (N=2601, 2598)52145
ALP High (N=2601, 2598)3527
AST High (N=2601, 2598)4040
Direct Bilirubin High (N=2601, 2593)2821
Total Bilirubin High (N=2601, 2597)87
SecondaryNumber of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests

Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use 0.9\* pre-dose or \> ULN if pre-dose \> ULN then use 1.1 \*pre-dose or \<LLN; Uric acid High: \> 1.5\* ULN, or if pre-dose \> ULN then use \> 2 \*pre-dose.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · participants
Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests
participantsApixabanEnoxaparin + Warfarin
Creatine Kinase High (N=2601, 2596)2024
Uric Acid High (N=2601, 2596)63
Total Protein Low (N=2601, 2596)1516
Total Protein High (N=2601, 2596)00
SecondaryNumber of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests

All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.

Time frame:
Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
Reported as:
Number · participants
Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests
participantsApixabanEnoxaparin + Warfarin
Blood in Urine High (N=2289, 2273)85127
Glucose in Urine High (N=2289, 2273)4631
Leukocyte Esterase in Urine High (N=2289, 2273)105102
Protein in Urine High (N=2289, 2273)4150
RBC + WBC in Urine High (N=1685, 1719)359361
RBC in Urine High (N=1293, 1389)111140
WBC in Urine High (N=1354, 1361)274263

Adverse events

Collected over Day 1 up to 24 Weeks + 2 Days or 355 Days (for those participants who discontinued early)/. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban—417/2,676 (15.6%)1,014/2,676 (37.9%)
Enoxaparin/Warfarin—410/2,689 (15.2%)1,207/2,689 (44.9%)
Most frequent serious events
Showing 10 of 484
Most frequent serious events
EventApixabanEnoxaparin/Warfarin
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders24/267638/2689
DEEP VEIN THROMBOSISVascular disorders20/267633/2689
PNEUMONIAInfections and infestations16/267612/2689
OVERDOSEInjury, poisoning and procedural complications15/267611/2689
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders8/267614/2689
HAEMATURIARenal and urinary disorders5/267613/2689
NON-CARDIAC CHEST PAINGeneral disorders9/26766/2689
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders9/26766/2689
DYSPNOEARespiratory, thoracic and mediastinal disorders9/26765/2689
URINARY TRACT INFECTIONInfections and infestations8/26763/2689
Most frequent other events
Showing 10 of 26
Most frequent other events
EventApixabanEnoxaparin/Warfarin
HEADACHENervous system disorders169/2676167/2689
EPISTAXISRespiratory, thoracic and mediastinal disorders77/2676144/2689
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders119/2676130/2689
OEDEMA PERIPHERALGeneral disorders93/2676111/2689
DIARRHOEAGastrointestinal disorders100/2676106/2689
NAUSEAGastrointestinal disorders81/2676106/2689
ALANINE AMINOTRANSFERASE INCREASEDInvestigations30/2676105/2689
NASOPHARYNGITISInfections and infestations104/267698/2689
CONTUSIONInjury, poisoning and procedural complications48/267697/2689
URINARY TRACT INFECTIONInfections and infestations92/267682/2689

Baseline characteristics

Randomized Participants

Age, Continuous
Age, Continuous(years)ApixabanEnoxaparin + WarfarinTotal
Mean57.2 ± 15.9856.7 ± 16.0156.9 ± 16.00
Age, Customized
Age, Customized(participants)ApixabanEnoxaparin + WarfarinTotal
Less than (<) 65172917623491
65 to < 755605701130
Greater than, equal to (>=) 75402372774
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanEnoxaparin + WarfarinTotal
Female112211062228
Male156915983167
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ApixabanEnoxaparin + WarfarinTotal
White221822434461
Black or African American10698204
American Indian or Alaska Native628
Asian227226453
Other Race8985174
Race Not Reported455095
Hispanic or Latino201838
Not Hispanic or Latino367380747
Ethnicity Not Reported230423064610
Region of Enrollment
Region of Enrollment(participants)ApixabanEnoxaparin + WarfarinTotal
Portugal10919
United States387398785
Hong Kong213
Spain5651107
Ukraine213211424
Israel162163325
Russian Federation178174352
Italy167169336
India10199200
France140149289
Malaysia022
Australia5664120
Denmark6972141
South Africa7077147
China113114227
Korea, Republic of224
Austria403979
Czech Republic140134274
Hungary145128273
Mexico5957116
Canada147152299
Argentina171633
Poland6059119
Brazil7781158
Singapore5510
Romania334174
Norway403272
Germany202205407
Qualifying index Venous Thromboembolic Embolism
Qualifying index Venous Thromboembolic Embolism(participants)ApixabanEnoxaparin + WarfarinTotal
Provoked Index VTE272272544
Unprovoked Index VTE241624294845
Not Reported336
Index Event Classification
Index Event Classification(participants)ApixabanEnoxaparin + WarfarinTotal
Proximal DVT177818143592
PE9138901803
Adjudicated Proximal DVT174917833532
Adjudicated PE9309061836
08

Study locations

382 sites
  • Alabama Clinical Therapeutics, Llc
    Birmingham, Alabama 35235, United States
  • Horizon Research Group, Inc.
    Mobile, Alabama 36608, United States
  • Fort Smith Lung Center
    Fort Smith, Arkansas 72901, United States
  • University Of Arkansas For Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Beaver Medical Group
    Banning, California 92220, United States
  • University Of California San Francisco-Fresno
    Fresno, California 93701, United States
  • University Of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Chest Medicine & Critical Care Medical Gr. Inc.
    San Diego, California 92123, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Harbor Ucla Medical Center
    Torrance, California 90509, United States
  • New West Physicians
    Golden, Colorado 80401, United States
  • Drogue Medical, Llc
    Wheat Ridge, Colorado 80033, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • Dept Of Internal Med, Sect Of Pulmonary & Critical Care Med
    New Haven, Connecticut 06510, United States
  • George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Bay Pines Va Healthcare Systems
    Bay Pines, Florida 33744, United States
  • Daniel G. Lorch, Jr, Md, Cpi
    Brandon, Florida 33511, United States
  • Research Alliance, Inc.
    Clearwater, Florida 33756, United States
  • River City Clinical Research
    Jacksonville, Florida 32207, United States
  • Pasadena Center For Medical Research
    St. Petersburg, Florida 33707, United States
  • Tampa Clinical Research
    Tampa, Florida 33624, United States
  • Office Of Michele S. Maholtz Md
    Vero Beach, Florida 32960, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Atlanta Pulmonary Group
    Atlanta, Georgia 30342, United States
  • Atlanta Institute For Medical Research, Inc
    Decatur, Georgia 30030, United States
  • Chatham Hospitalists
    Savannah, Georgia 31405, United States
  • Gateway Cardiology. P.C
    Jerseyville, Illinois 62052, United States
  • West Suburban Medical Center
    Oak Park, Illinois 60302, United States
  • Infectious Disease Of Indiana Psc
    Carmel, Indiana 46032, United States
  • Heartland Vascular Medicine And Surgery
    Windsor Heights, Iowa 50324, United States
  • Kentucky Lung Clinic
    Hazard, Kentucky 41701, United States
  • Univ. Of Kentucky Dept. Of Surgery
    Lexington, Kentucky 40536, United States
  • Research Integrity, Llc
    Owensboro, Kentucky 42303, United States
  • Pen Bay Medical Center
    Rockport, Maine 04856, United States
  • Anne Arundel Medical Center
    Annapolis, Maryland 21401, United States
  • R Adams Cowley Shock Trauma Center
    Baltimore, Maryland 21201, United States
  • Medstar Research Health Institute
    Baltimore, Maryland 21237, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • Mississippi Medical Research, Llc
    Picayune, Mississippi 39466, United States
  • University Of Missouri-Columbia
    Columbia, Missouri 65212, United States
  • Veterans Affairs Medical Center
    Kansas City, Missouri 64128, United States
  • Washington University School Of Medicine
    St Louis, Missouri 63110, United States
  • St. John'S Mercy Medical Center
    St. Louis, Missouri 63141, United States
  • Mercury Street Medical Group, Pllc
    Butte, Montana 59701, United States
  • Great Falls Clinic, Llp
    Great Falls, Montana 59405, United States
  • Internal Medical Associates Of Grand Island, P.C
    Grand Island, Nebraska 68803, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07962, United States
  • Pulmonary & Critical Care Services, Pc
    Albany, New York 12205, United States
  • Kaleida Health System
    Buffalo, New York 14209, United States
  • Richmond University Medical Center
    Staten Island, New York 10310, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Rex Healthcare
    Raleigh, North Carolina 27607, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Wilmington Medical Research
    Wilmington, North Carolina 28401, United States
  • Clinical Trials Of America, Inc.
    Winston Salem, North Carolina 27103, United States
  • Altru Health System Clinic
    Grand Forks, North Dakota 58201, United States
  • Huron Hospital
    Cleveland, Ohio 44112, United States
  • Remington Davis Inc.
    Columbus, Ohio 43215, United States
  • Oregon Health Science University
    Portland, Oregon 97239, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Greenville Hospital System
    Greenville, South Carolina 29615, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Kore Cv Research
    Jackson, Tennessee 38305, United States
  • Primecare Medical Group
    Houston, Texas 77024, United States
  • Cancer Care Centers Of South Texas
    San Antonio, Texas 78229, United States
  • University Of Utah Medical Center
    Salt Lake City, Utah 84132, United States
  • Lake Washington Vascular, Pllc
    Bellevue, Washington 98004, United States
  • Franciscan Research Center
    Tacoma, Washington 98405, United States
  • Local Institution
    Ciudad Autonoma De Buenos Aire, Buenos Aires C1180AAX, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    Rosario, Santa Fe S2000CVB, Argentina
  • Local Institution
    Rosario, Santa Fe S2000DSV, Argentina
  • Local Institution
    Buenos Aires, C1280AEB, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    Corrientes, 3400, Argentina
  • Local Institution
    Garran, Australian Capital Territory 2605, Australia
  • Local Institution
    Concord, New South Wales 2139, Australia
  • Local Institution
    Kogarah, New South Wales 2217, Australia
  • Local Institution
    Lismore, New South Wales 2480, Australia
  • Local Institution
    Randwick, New South Wales 2031, Australia
  • Local Institution
    Herston, Queensland 4029, Australia
  • Local Institution
    Adelaide, South Australia 5000, Australia
  • Local Institution
    Bedford Park, South Australia 5042, Australia
  • Local Institution
    Hobart, Tasmania 7000, Australia
  • Local Institution
    Box Hill, Victoria 3128, Australia
  • Local Institution
    Clayton, Victoria 3168, Australia
  • Local Institution
    Ringwood East, Victoria 3135, Australia
  • Local Institution
    Windsor, Victoria 3181, Australia
  • Local Institution
    Perth, Western Australia 6001, Australia
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Innsbruck, 6020, Austria
  • Local Institution
    Vienna, 1090, Austria
  • Local Institution
    Vienna, 1100, Austria
  • Local Institution
    Vienna, 1140, Austria
  • Local Institution
    Vienna, 1160, Austria

Showing the first 100 of 382 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16. PubMed 35570249 ↗
  • Cohen AT, Pan S, Byon W, Ilyas BS, Taylor T, Lee TC. Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. Adv Ther. 2021 Jun;38(6):3003-3018. doi: 10.1007/s12325-021-01716-8. Epub 2021 Apr 22. Erratum In: Adv Ther. 2021 Aug;38(8):4596-4597. doi: 10.1007/s12325-021-01822-7. PubMed 33890242 ↗
  • Cohen AT, Agnelli G, Buller HR, Gallus A, Raskob GE, Sanders P, Thompson J, Weitz JI. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar;119(3):461-466. doi: 10.1055/s-0038-1676983. Epub 2019 Jan 16. PubMed 30650446 ↗
  • Liu X, Johnson M, Mardekian J, Phatak H, Thompson J, Cohen AT. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc. 2015 Dec 1;4(12):e002340. doi: 10.1161/JAHA.115.002340. PubMed 26627879 ↗
  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1. PubMed 23808982 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Mar 26, 2008
Start
Jul 2008
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Apr 10, 2014
Last update
Apr 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00643201
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 26, 2008
Start date
Jul 2008
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Apr 10, 2014
Last update
Apr 21, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion